Loading...

LAURUSLABS Laurus Labs Ltd Earnings Reports Announcement

Lrs

LRSL

Laurus Labs Ltd

(LAURUSLABS)

2026 Announcement

Trading window closure

Statutory Auditor Appointment

Investor Meeting

Analyst / Investor Meet Sch...

Merger of Equals

ESG Recognition

ESG score disclosure

Reg 29(2) disclosure

Investor Meeting

Transcript release

Newspaper Advertisement

Conference call recording

Financial results

Investor Presentation

Unaudited Financial Results

Earnings Release

Earnings Conference Call

Board Meeting Intimation

Regulatory compliance

Trading Window Closure

Equity Investment

Analyst / Investor Meet

Analyst / Investor Meet

Analyst & Investor Meetings

Newspaper Publication

Earnings Call Transcript

Financial Results Update

Financial Results Update

Investor Presentation

Dividend Approved

Board Meeting Outcome

Financial Results

Earnings Call Invite

Compliance Certificate

Investor Presentation

Investor Meetings

Merger Announcement

Investor Conference

Scheme of Arrangement

Earnings Call Update

Financial Results Published

Q1 FY26 Results

Q1 Earnings Report

Investment in KRKA

Compliance Certificate

Earnings Call Invite

Credit Rating Update

Investment Update

Investor Meetings

New VP Appointment

AGM Notice Publication

AGM Notice Published

Investor Meeting Scheduled

Annual Compliance Report

Newspaper Publication

Earnings Call Transcript

Financial Results Published

Q4 FY25 Results

Q4 FY25 Results

Investor Presentation

USFDA Inspection Report

Compliance Certificate

Earnings Call Invite

Correction of Dates

Acquisition Announcement

Executive Re-Appointments

Stock Options Granted

Acquisition Update

Investment in KRKA

Investor Conference Partici...

USFDA Inspection Update

Earnings Call Summary

Financial Results Publication

Investor Conference Call

Q3 FY25 Results

Q3 FY 2025 Results

FDA Inspection Result

Tax Penalty Imposed

Compliance Certificate

Earnings Call Invite

Investment Update

Equity Investment Secured

Investment in Subsidiary

Investor Meeting Scheduled

Investor Meetings

Q2 FY25 Earnings Call

Financial Results Publication

Q2 Earnings Call

Board Compliance Update

Q2 FY25 Results

Investor Presentation

Compliance Certificate

Director Appointment

Investor Meeting

New R&D Facility

Successful FDA Audit

Successful FDA Audit

Postal Ballot Notice

Director Appointment

Board Composition Fine

Newspaper Publication

Results Conference Call

Q1 FY25 Results

Investor Presentation

Directorate Change

Directors Appointment Confi...

Certificate Submission

USFDA Inspection Outcome

Credit Rating Update

Newspaper Advertisement

Credit Rating Confirmation

Advertisement Publication

Meeting Intimation

Compliance Submission

FDA Inspection Response

Financial Results Announcement

Investor Presentation

USFDA Inspection

Earnings Conference Call

Compliance Certificate Subm...

Certificate Issuance

Certificate Receipt

Equity Infusion

Acquisition Update

Investor Conferences

Joint Venture Agreement

Conference Call Audio Recor...

Investor Presentation

Financial Results

Grant of Stock Options

Conference Call Invite

Certificate submission

Inspection Observation

Equity Allotment

Investor Presentation

Analyst/Investor Meeting

Meeting Schedule

Acquisition Update

Conference Call Recording

Related Party Transactions ...

Change in Directorate

Financial Results

Investor Presentation

Acquisition Update

CAR-T Therapy Approval

Conference Call Invite

Certificate confirmation

Investor Meetings

Acquisition of Laurus Bio P...

Analyst/Investor Meeting

Analyst Meetings

Earnings Releases

Financial Statements

Earnings Releases

Credit Rating Affirmation

Corporate Meeting

Analyst/Investor Meet

Equity, Debt, VC, Private E...

AGM Announcement

US FDA Inspection

Equity Investments

Minority stake acquisition

Investor Meetings

SEBI LODR Regulations Compl...

Investor Meetings

Earnings Call Transcript

Changes in Revenue Recognition

External Links:

Data:

Laurus Labs reports 9M FY2026 revenue of ₹5,001 crore with 26.1% EBITDA margin and 60.1% gross margin; investor presentation released highlighting CDMO and Generics momentum and capex plans.

AI Assistant

Laurus Labs Ltd

2026

Announcement

Find Answers

Ask about any part of the document to get insights, explanations, or key details.